Tareq Abadl on NETs: A Clinical and Laboratory Overview for Thrombosis Management
Tareq Abadl, Medical Laboratory Specialist and Director of the Blood Bank at Dr. Abdelkader Al-Mutawakkil Hospital, posted on LinkedIn:
“Neutrophil Extracellular Traps (NETs) and Platelet–Neutrophil Aggregates
- Short Introduction
NETs are mesh-like webs of chromatin coated with neutrophil proteins (histones, MPO, elastase). They trap pathogens but also create a procoagulant scaffold that binds platelets, activates coagulation, and promotes thrombosis. NET-driven thrombosis is seen in sepsis, severe COVID-19, cancer, autoimmune diseases, and device-related clotting.
- When to Suspect NET-Driven Thrombosis
Unexplained or recurrent thrombosis with significant inflammation (↑ CRP, ↑ ferritin) or neutrophilia.
Thrombosis with severe infection, malignancy, autoimmune flare, ECMO/LVAD/HD devices, or poor response to standard anticoagulation.
Microvascular thrombosis with organ dysfunction out of proportion to typical causes.
- Practical Laboratory Assays
MPO–DNA or nucleosome ELISA → detects NET fragments (sensitive, limited specificity).
Citrullinated histone H3 (H3Cit) ELISA/Western → more specific for PAD4-dependent NETosis.
Cell-free DNA (cfDNA) → sensitive but non-specific.
Flow cytometry for platelet–neutrophil aggregates (CD45+/CD15+/CD66b+ with CD41+/CD61+).
Functional assays: thrombin generation ± DNase or NET inhibitors.
Histology/IF (DNA + MPO/H3Cit colocalization) → gold standard for NET-rich thrombus.
- Specimen and Pre-Analytical Requirements
Tube type: follow assay SOP; avoid heparin in DNA-based assays.
Processing: double-spin plasma; avoid buffy coat contamination.
Storage: aliquot, freeze at −80°C, avoid repeated freeze–thaw.
Documentation: infection status, inflammatory markers, device exposure, anticoagulation therapy, processing times.
- How to Interpret
↑ MPO–DNA or H3Cit → supports NET involvement; must correlate clinically.
↑ Platelet–neutrophil aggregates → indicates platelet-driven neutrophil activation/NET potential.
Functional confirmation: reduced thrombin generation after DNase supports NET-dependent clotting.
Trend > single value: rising markers before events are more meaningful.
- Clinical Implications
NETs may be targeted using DNase, anti-inflammatory therapy, or investigational PAD4 inhibitors—coordinate with hematology/critical care.
Device-related NET-rich thrombosis may require optimizing device flow/coating plus tailored anticoagulation.
NET markers are adjunctive, not a replacement for standard diagnostics.
- Pitfalls and Limitations
NET assays lack standardization; always report method and reference ranges.
Delayed processing or leukocyte lysis can cause false elevations.
cfDNA is non-specific; H3Cit is more specific but assay-dependent.
Many assays are still research-level rather than routine clinical tests.”
Stay updated with Hemostasis Today.
-
Jul 3, 2026, 23:08For Jatinder Minhas, The Strength of Simulation Training Is Learning Together Across Disciplines – ESO
-
Jul 3, 2026, 22:47Khaled Musallam: Caring for Women with Thalassemia From Puberty to Pregnancy and Beyond
-
Jul 3, 2026, 21:25Matteo Foschi: Happy to Join the Italian Stroke Association Summer School
-
Jul 3, 2026, 20:39Maha Othman: Excited to Present on PPH for The Lancet Haematology Commission on Global Female Health
-
Jul 3, 2026, 19:15Edward Lee Carter: Anticoagulation Drift – The Patient Changes, the Plan Should Too
-
Jul 3, 2026, 19:15Marcelo Soares: Cytokine and Lymphocyte Profiles of Cancer Patients With COVID-19
-
Jul 3, 2026, 19:13Anwar Elshikh: Calciphylaxis and Skin Issues in Renal Failure Patients
-
Jul 3, 2026, 19:11Amr M. Fahmi: Genotype-Guided Warfarin Dosing in the Arab Population
-
Jul 3, 2026, 19:10Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics